Bart Herbison, executive director at NSAI in Nashville, sat down with hit songwriters Will Hoge and Eric Paslay to get the ...

Eli Lilly & Co.’s stock soared 14% Thursday, to put it on track for its biggest one-day gain in about 25 years, after the drugmaker reported positive results from a late-stage trial of a GLP-1 ...

Eli Lilly’s (NYSE:LLY) stock faced a notable decline following the company’s announcement of a reduced profit forecast, despite delivering first-quarter results that surpassed Wall Street ...

Eli Lilly said the revision reflects a $1.57 billion deal charge recorded in the first quarter, which is primarily related to its acquisition of a certain oral cancer drug from Scorpion Therapeutics.

Growth stocks often don't come cheap, especially when their prospects look great, as is the case with Eli Lilly (NYSE: LLY). It is the most valuable healthcare company in the world, with a market ...

Eli Lilly isn't done in developing new weight loss treatments. In fact, the best may still be to come, as it's working on a pill, which could be a game changer for the industry.

Eli Lilly is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 trillion stock and the first healthcare company to do so.Trading at $852 per share, LLY ...

Eli Lilly, the drugmaker behind the blockbuster weight loss drug Zepbound, is suing four telehealth companies for allegedly selling illegal copies of the drug made by compounding pharmacies.

Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its diabetes treatment Mounjaro, escalating its battle against unauthorized ...

Eli Lilly is suing four telehealth companies selling compounded versions of the pharmaceutical giant's weight loss drug Zepbound and its diabetes treatment Mounjaro, the company's latest attempt ...